BIOMAT Database Logo BIOMAT Database Logo

Long-lasting movement disorder induced by intravenous phenytoin administration for status epilepticus. A case report. 1988

K Kurata, and H Kido, and K Kobayashi, and N Yamaguchi
Department of Neuropsychiatry, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Japan.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008590 Meningoencephalitis An inflammatory process involving the brain (ENCEPHALITIS) and meninges (MENINGITIS), most often produced by pathogenic organisms which invade the central nervous system, and occasionally by toxins, autoimmune disorders, and other conditions. Cerebromeningitis,Encephalomeningitis,Cerebromeningitides,Encephalomeningitides,Meningoencephalitides
D010672 Phenytoin An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. Diphenylhydantoin,Fenitoin,Phenhydan,5,5-Diphenylhydantoin,5,5-diphenylimidazolidine-2,4-dione,Antisacer,Difenin,Dihydan,Dilantin,Epamin,Epanutin,Hydantol,Phenytoin Sodium,Sodium Diphenylhydantoinate,Diphenylhydantoinate, Sodium
D004409 Dyskinesia, Drug-Induced Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199) Dyskinesia, Medication-Induced,Medication-Induced Dyskinesia,Drug-Induced Dyskinesia,Drug-Induced Dyskinesias,Dyskinesia, Drug Induced,Dyskinesia, Medication Induced,Dyskinesias, Drug-Induced,Dyskinesias, Medication-Induced,Medication Induced Dyskinesia,Medication-Induced Dyskinesias
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013226 Status Epilepticus A prolonged seizure or seizures repeated frequently enough to prevent recovery between episodes occurring over a period of 20-30 minutes. The most common subtype is generalized tonic-clonic status epilepticus, a potentially fatal condition associated with neuronal injury and respiratory and metabolic dysfunction. Nonconvulsive forms include petit mal status and complex partial status, which may manifest as behavioral disturbances. Simple partial status epilepticus consists of persistent motor, sensory, or autonomic seizures that do not impair cognition (see also EPILEPSIA PARTIALIS CONTINUA). Subclinical status epilepticus generally refers to seizures occurring in an unresponsive or comatose individual in the absence of overt signs of seizure activity. (From N Engl J Med 1998 Apr 2;338(14):970-6; Neurologia 1997 Dec;12 Suppl 6:25-30) Absence Status,Complex Partial Status Epilepticus,Generalized Convulsive Status Epilepticus,Non-Convulsive Status Epilepticus,Petit Mal Status,Simple Partial Status Epilepticus,Grand Mal Status Epilepticus,Status Epilepticus, Complex Partial,Status Epilepticus, Electrographic,Status Epilepticus, Generalized,Status Epilepticus, Generalized Convulsive,Status Epilepticus, Grand Mal,Status Epilepticus, Non-Convulsive,Status Epilepticus, Simple Partial,Status Epilepticus, Subclinical,Electrographic Status Epilepticus,Generalized Status Epilepticus,Non Convulsive Status Epilepticus,Status Epilepticus, Non Convulsive,Status, Absence,Status, Petit Mal,Subclinical Status Epilepticus

Related Publications

K Kurata, and H Kido, and K Kobayashi, and N Yamaguchi
Phenytoin-induced movement disorder associated with intravenous administration for status epilepticus.
August 1985, Clinical pediatrics,
K Kurata, and H Kido, and K Kobayashi, and N Yamaguchi
Phenytoin induced status epilepticus.
April 2010, Neurosciences (Riyadh, Saudi Arabia),
K Kurata, and H Kido, and K Kobayashi, and N Yamaguchi
Phenytoin induced status epilepticus.
October 2010, Neurosciences (Riyadh, Saudi Arabia),
K Kurata, and H Kido, and K Kobayashi, and N Yamaguchi
A Case of Phenytoin-induced Rhabdomyolysis in Status Epilepticus.
June 2016, Journal of epilepsy research,
K Kurata, and H Kido, and K Kobayashi, and N Yamaguchi
Status epilepticus. The role of intravenous phenytoin.
September 1980, JAMA,
K Kurata, and H Kido, and K Kobayashi, and N Yamaguchi
Hypoglycaemia induced by phenytoin treatment for partial status epilepticus.
September 2002, Journal of neurology, neurosurgery, and psychiatry,
K Kurata, and H Kido, and K Kobayashi, and N Yamaguchi
Combination therapy for status epilepticus: intravenous diazepam and phenytoin.
January 1983, Advances in neurology,
K Kurata, and H Kido, and K Kobayashi, and N Yamaguchi
Intravenous lacosamide or phenytoin for treatment of refractory status epilepticus.
May 2014, Acta neurologica Scandinavica,
K Kurata, and H Kido, and K Kobayashi, and N Yamaguchi
[Chlorpromazine-induced status epilepticus: a case report].
January 2013, Srpski arhiv za celokupno lekarstvo,
K Kurata, and H Kido, and K Kobayashi, and N Yamaguchi
Randomized study of intravenous valproate and phenytoin in status epilepticus.
September 2007, Seizure,
Copied contents to your clipboard!